U.S. Topical Pain Relief Market Global Trends, Market Share, Industry Size, GroPosted by diwanji a on September 18th, 2019 U.S. Topical Pain Relief Market is estimated to value over USD 3.4 billion by 2026 end and register a CAGR of over 5% during the forecast period 2019 to 2026.
The U.S. topical pain relief market growth is primarily steered by an increase in the prevalence of diabetic neuropathy, arthritis and other orthopaedic conditions, leading to pain. Other factors boosting the market growth are an increase in topical pain relief product adoption owing to a reduction in side effects in comparison with oral pain relief, an increase in demand for topical pain relief by athletes and a soaring geriatric population across the United States.
Although, factors like topical pain relief medications have a strong and unpleasant smell and can cause irritation of the skin that can impede the U.S. topical pain relief market growth. On the contrary, the development of an online platform for topical therapeutics is projected to provide profitable opportunities for market growth.
Non-Opioids is Projected to be a Lucrative Segment Over the Forecast Period
The U.S. topical pain relief market is segmented based on therapeutic class, formulation, distribution channel and type. Based on therapeutic class, the market is bifurcated into non-opioids and opioids. The non-opioids segment is further divided into methyl salicylate, capsaicin, lidocaine, nonsteroidal anti-inflammatory drugs (NSAIDs), and other non-opioids. The opioids segment is further fragmented into fentanyl and buprenorphine. The non-opioids segment had the largest U.S. topical pain relief market share in 2017 and is predicted to showcase this trend over the forecast period due to easy availability and high preferability of non-opioids drugs.
By type, the U.S. topical pain relief market is fragmented into and over-the-counter (OTC) relief and prescription pain relief. Over-the-counter pain relief segment gauged the largest U.S. topical pain relief market share in 2017 owing to high demand for topical pain relief products by athletes and its easy availability. Depending on the type of formulation, the market is classified into gel, cream, patch, spray and others. Cream-based pain relief segment gauged the largest market share in 2017 owing to high product availability coupled with lesser side effects and high success rate. On the contrary, patch pain relief segment is predicted to grow at a high CAGR over the forecast period.
The key players of this market include Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc., Pfizer Inc., Reckitt Benckiser Group Plc., Sanofi S.A., Topical BioMedics, Inc., AdvaCare Pharma, Sun Pharmaceutical Industries Ltd., and Nestle S.A.
U.S Topical Pain Relief Market Segmentation:By Therapeutic Class
By Type
By Formulation
By Distribution Channel
Purchase a Copy & Ask For Discount: https://www.futurewiseresearch.com/request-sample.aspx?id=3402&page=askfordiscount
FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth
Objectives of the Study:
Table of ContentsCHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Top player positioning, 2018
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in prevalence of arthritis
3.4.1.2. Growth in geriatric population
3.4.1.3. High demand for topical pain relief products by sportsperson
3.4.1.4. Lesser side effects caused by topical pain relief products as compared to oral medicines
3.4.2. Restraints
3.4.2.1. Topical pain relief sometimes cause skin irritants
3.4.2.2. Topical pain relief is characterized by unpleasant odor
3.4.3. Opportunities
3.4.3.1. Emergence of online pharmacy
3.4.4. Impact analysis
3.5. U.S. patent analysis by year
CHAPTER 4: U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Non-opioids
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type
4.2.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDS)
4.2.2.1.1. Market size and forecast
4.2.2.2. Methyl salicylates
4.2.2.2.1. Market size and forecast
4.2.2.3. Capsaicin
4.2.2.3.1. Market size and forecast
4.2.2.4. Lidocaine
4.2.2.4.1. Market size and forecast
4.2.2.5. Other non-opioids
4.2.2.5.1. Market size and forecast
4.3. Opioids
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type
4.3.2.1. Buprenorphine
4.3.2.1.1. Market size and forecast
4.3.2.2. Fentanyl
4.3.2.2.1. Market size and forecast
CHAPTER 5: U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Cream
5.2.1. Market size and forecast
5.3. Gel
5.3.1. Market size and forecast
5.4. Spray
5.4.1. Market size and forecast
5.5. Patch
5.5.1. Market size and forecast
5.6. Others
5.6.1. Market size and forecast
CHAPTER 6: U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE
6.1. Overview
6.1.1. Market size and forecast
6.2. Prescription pain relief
6.2.1. Market size and forecast
6.3. Over-the-counter pain relief
6.3.1. Market size and forecast
CHAPTER 7: U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL
7.1. Overview
7.1.1. Market size and forecast
7.2. Pharmacies & drug stores
7.2.1. Market size and forecast
7.3. e-Commerce
7.3.1. Market size and forecast
7.4. Retail & grocery stores
7.4.1. Market size and forecast
CHAPTER 8: COMPANY PROFILES
8.1. AdvaCare Pharma
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio
8.2. GlaxoSmithKline plc.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Johnson & Johnson
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance
8.4. Nestlé S.A.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance
8.5. Novartis AG
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product Portfolio
8.5.5. Business performance
8.6. Pfizer Inc.
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance
8.7. Reckitt Benckiser Group plc
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance
8.8. Sanofi
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments
8.9. Sun Pharmaceutical Industries Ltd.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments
8.10. Topical BioMedics, Inc.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Key strategic moves and developments
Chapter 9 Research Finding and Conclusion
Chapter 10 Research Methodology
About FutureWise Research:
We specialise in high-growth niche markets, assuring flexibility, agility and customised solutions for our clients. Through in-depth market insights and consultancy, we present our clients with the tools they need to be at the forefront of their industry – a position secured for far more than the near future.
Contact Us:
Company Name: FutureWise Research
Contact Person: Vinay Thaploo
Phone: +44 141 628 9353 / +1 970 279 4295
City: Leeds
Country: United Kingdom
Like it? Share it! More by this author |